106 articles - From Friday Jun 27 2025 to Friday Jul 04 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Endoscopy |
|---|
Quality standards and curriculum for training in cholangiopancreatoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. A trainee's principal trainer should be an experienced trainer ideally with at least 3 years of experience in undertaking independent cholangioscopy to the determined quality standards. Competence in cholangioscopy should be defined as the ability to successfully perform the procedure effectively without trainer assistance in 80 % of procedures. |
| Gastroenterology |
| Gastrointest Endosc |
meta-analyses and systematic reviews
| Aliment Pharmacol Ther |
|---|
Meta-Analysis: Effects of Steatotic Liver Disease-Associated Genetic Risk Alleles on Longitudinal Outcomes. Variants in PNPLA3, TM6SF2 and MBOAT7 are significantly associated with hepatic outcomes, especially with advanced baseline liver disease, with modest effects on extrahepatic outcomes. Routine genotyping may improve risk stratification in SLD patients with advanced liver disease. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
Pain and Sedative Medication Use Among Individuals With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study. A substantial proportion of individuals with IBD are prescribed pain and sedative medications, including long-term and co-prescriptions. Identifying high-risk patients is essential to ensure they are prioritised for limited resources, such as psychological therapies, as alternatives to harmful prescriptions. |
Research Communication: Prevalence of Acute Reactions After Gluten Ingestion in Patients With Coeliac Disease-A Retrospective Study. Patients on gluten-free diet may experience acute symptoms after accidental gluten ingestion. Further research is needed on frequency, triggers, and implications. |
| Am J Gastroenterol |
Adding clip before endoscopic cyanoacrylate injection decreases ectopic embolisms in gastric varices: a randomized controlled trial. Clipping before endoscopic cyanoacrylate injection reduces the risk of ectopic embolism in patients with fundal varices with a portal-systemic shunt, without compromising safety or efficacy. |
Bloating and distention patients form 6 distinct latent clusters based on symptoms, diet, psychosocial and quality of life parameters. Bloating and distention patients are likely driven by variable influences of dietary, psychological and bowel dysfunction. Further studies are needed to identify mechanisms and titrate treatment suited to specific mechanistic drivers. |
Effect of second sigmoid colon intubation during colonoscopy on adenoma detection rate in overweight and obese patients: A prospective randomized controlled trial. Using a second intubation of the sigmoid colon can effectively enhance the detection rate of sigmoid colon adenomas and polyps. |
Geographical Distance from Transplant Center and Impact on Waitlist Outcomes and Healthcare Utilization Pre-Listing. Geographical distance does not significantly impact LT waitlist mortality or receipt of LT. However, differences in healthcare utilization suggest disparities may still manifest with a negative impact on patients in the pre-LT setting. |
Switching to entecavir >3 months before the end of tenofovir-based therapy in HBeAg-negative patients may reduce early relapse and hepatitis flare. The results confirm that the timing of clinical relapse is associated with the last antiviral agent used before EOT. Furthermore, the ETV-switching strategy may reduce clinical relapse and hepatitis flare and the severity of hepatitis flare within 24 weeks after EOT. This strategy seems clinically useful and important for a safer cessation of TDF-based treatment. |
| Clin Gastroenterol Hepatol |
Epidemiology of compensated Advanced Chronic Liver Disease (cACLD) in the United States: Insights from NHANES 2017-2020. Approximately 5 million people in the US may have cACLD, and another 8 million may have possible cACLD. The majority of cACLD patients tend to be male, diabetic, and obese. The high rate of unawareness underscores the need for enhanced screening and surveillance strategies to improve early detection and management. |
| Endoscopy |
A novel artificial intelligence-based system for quality monitoring during esophagogastroduodenoscopy: a multicenter randomized controlled study. The use of EQCA during EGD was associated with increased detection of UGI cancer and precancerous lesions. Our novel EQCA system can be an effective tool for monitoring real-time EGD quality. |
| Gastrointest Endosc |
Follow-up of 35 appendiceal orifice neoplasms resected by endoscopic full-thickness resection. In conclusion, EFTR is an effective technique for the curative resection of select, small (<15mm) Paris 0-IIa AO lesions. Appendicitis is a relatively common adverse event but often managed conservatively. The long-term significance post-EFTR fistulas remains unclear. Caution should be exercised when considering EFTR in a patient with prior regional surgery. |
| Gut |
Lifestyle factors, genetic susceptibility and risk of incident diverticulitis: an integrated analysis of four prospective cohort studies and electronic health records-linked biobank. Maintaining a healthy lifestyle was associated with a reduced risk of developing diverticulitis, regardless of population differences and genetic susceptibilities. |
Nuclear Pirin promotes HCC by acting as a key inflammation-facilitating factor. We elucidate a novel redox-dependent regulatory mechanism governing the nuclear localisation of PIR and its role in promoting liver inflammation and HCC progression. Our findings underscore the significance of cellular redox status in regulating PIR's activity and highlight the potential of targeting this pathway with antioxidants to mitigate HCC progression. |
| Hepatology |
Antibody response to microbiota antigens is associated with alcohol-related liver disease severity and predicts mortality. The antibody response to microbiota is associated with ALD severity and predicts the risk of severe outcomes. These results suggest a role for immune complexes in ALD pathogenesis and that antibody profiling has potential as a biomarker for clinical management of ALD patients. |
Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease. In addition to altering membrane transporter function by targeting IBAT/ASBT and NTCP, there are an array of potentially additive therapeutic approaches which include receptor agonists acting via nuclear receptor (FXR, PPAR)-mediated transcriptional modification of BA synthesis and transport genes and BA analogs such as norucholic acid (previously known as norUDCA) that undergo cholehepatic shunting. This article reviews established and emerging molecular and clinical rationales for therapeutic targeting of BA circulation and signaling in liver diseases with a specific focus on cholestatic disorders. |
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab-bevacizumab. The CRAPT-M model demonstrated robust OS prediction, offering a valuable tool for prognosis estimation and clinical decision-making in advanced HCC patients receiving AB. |
Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy. Distinct gut microbiota, but shared beneficial metabolites, particularly fecal acetate, are associated with durable response to combination immunotherapy and improved survival in both MASLD-HCC and V-HCC. Fecal acetate may serve as a potential biomarker and therapeutic target for optimizing HCC treatment. |
MIF-mediated crosstalk between THRSP+ hepatocytes and CD74+ lipid-associated macrophages in hepatic periportal zone drives MASH. Our study demonstrates that THRSP drives MASH progression by recruiting CD74+ LAMs mediated by MIF in hepatic PP zone, providing novel insights into the spatial zonation and crosstalk between lipogenic hepatocytes and LAMs that may result in novel therapies for MASH. |
The OGT-TFF2 axis mediates intrahepatic crosstalk and MASH pathogenesis. These results identify an OGT-TFF2 axis that mediates the crosstalk between hepatocytes and CD4 T cells during MASH pathogenesis, revealing a potential therapeutic target for the treatment of chronic liver disease. |
Tumor site influences efficacy of MEKi and immunotherapy combinations in pre-clinical model of cholangiocarcinoma. These findings identify myeloid cells as key mediators of both immunotherapy resistance and toxicity in CCA, highlighting the critical importance of tumor site and use of physiologically relevant pre-clinical models when evaluating immunotherapy strategies. |
Tumor-migrating peripheral Foxp3-high regulatory T cells drive poor prognosis in hepatocellular carcinoma. Peripheral Foxp3high Tregs migrate to tumor sites via the CCR5-CCL5 axis and mature in response to pro-inflammatory cytokines. The proportion of these Tregs in peripheral blood correlates with their presence in tumors, making them a potential biomarker for predicting HCC outcomes. |
| J Hepatol |
Antibodies elicited by hepatitis E vaccination in humans confer cross-genus protection against rat hepatitis E virus. These findings underscore the importance of antigenic site 1 in the design of broad-spectrum vaccines and therapeutics to mitigate the impact of diverse HEV genotypes on human health. IMPACT AND IMPLICATIONS rHEV spillover to humans represents an unprecedented threat. Significant antigenic differences between rHEV and bHEV may exacerbate the impact of viral hepatitis. Our study reveals that cross-reactive human antibodies can offer protection against rHEV infection. Cross-protective antibodies targeting antigenic site 1 can be used to inform the development of practical strategies for preventing rHEV infection. |
Phase 1 randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis. Rapirosiran exhibited an encouraging safety and tolerability profile, with robust reduction in liver HSD17B13 mRNA expression. Impact and implications Metabolic dysfunction-associated steatohepatitis (MASH) is a prevalent chronic liver disease with a high burden of disease. The hydroxysteroid 17-beta dehydrogenase 13 gene (HSD17B13) is implicated in the pathogenesis of MASH. Rapirosiran offers a novel mechanism to treat MASH by directly reducing hepatic HSD17B13 expression. In this Phase 1 study, rapirosiran demonstrated an encouraging safety and tolerability profile and resulted in robust reduction in liver HSD17B13 mRNA expression following two subcutaneous doses. The data support further development of rapirosiran as a potential treatment option for patients with MASH, a disease for which there is only one approved pharmacological treatment. Clinical trial number EUDRA-CT 2020-000847-29; NCT 04565717. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide. Most therapies used in IBD, particularly biologic therapies, appear safe and effective when used in patients with CKD, including those on renal replacement therapy. Caution should be considered when using conventional therapies and JAK inhibitors. |
| Clin Gastroenterol Hepatol |
| Gastroenterology |
Circadian Rhythms in Gastroenterology: The Biological Clock's Impact on Gut Health. These interventions aim to realign the circadian clock with external cues or optimize medication timing according to biological rhythms. Understanding the role of the circadian clock in GI conditions can provide preventive and therapeutic opportunities to reduce the burden of GI diseases. |
| Gut |
Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration. We also review comprehensively the therapies targeting barrier integrity and normalising intestinal permeability, including particular diets and supplements, and experimental and improved medications including larazotide acetate and IMU-856. Finally, we highlight the need for reliable biomarkers for evaluating increased permeability in coeliac disease and advocate for further research on therapies which normalise barrier function, particularly as a strategy to maintain remission. |
The dual role of IgG4 in immunity: bridging pathophysiology and therapeutic applications. This review examines the pathophysiological roles of IgG4 in the regulation of immune responses, highlighting its involvement in both homoeostasis and disease. Furthermore, it explores the therapeutic potential of harnessing IgG4's unique features, not only for IgG4-associated diseases, but also for other indications, where promoting beneficial IgG4 responses could offer therapeutic advantages. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Clin Gastroenterol Hepatol |
| Endoscopy |
| Gastrointest Endosc |
| Gut |
| Hepatology |
| J Hepatol |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Clin Gastroenterol Hepatol |
| Gastroenterology |
| Gut |
| J Neurogastroenterol Motil |